To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 1
This profile is validated by 1 label.

Company

Bimini Biotech BV

Bimini Biotech BV_logo
25
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Bimini Biotech is an oncology therapeutics spin-off from University Medical Center Utrecht, based on years of research by the group of Prof. dr. Ger Strous, in the role of the growth hormone receptor (GHR) in cancer, metabolic and aging disorders.

Abcoude, Utrecht, Netherlands

Send a message

English

Bimini Biotech BV

English

BIMINI Biotech was founded based on 30 years of work on the GH/IGF-1 axis at the lab of Prof. Ger Strous. Our lead compounds have shown extremely promising in vitro and in vivo efficacy for various cancer types (lung, skin, bone, colon). We are currently pursuing our lead assets for the treatment of colorectal cancer, a deadly disease with a huge socio-economic impact. Our approach is based on a novel method of targeting the GH/IGF-1 axis via a unique mode of action, thus delivering solid...

See more

BIMINI Biotech was founded based on 30 years of work on the GH/IGF-1 axis at the lab of Prof. Ger Strous. Our lead compounds have shown extremely promising in vitro and in vivo efficacy for various cancer types (lung, skin, bone, colon). We are currently pursuing our lead assets for the treatment of colorectal cancer, a deadly disease with a huge socio-economic impact. Our approach is based on a novel method of targeting the GH/IGF-1 axis via a unique mode of action, thus delivering solid efficacy results.

We aim to become a leading innovator in GHR based therapeutics in oncology, metabolic disorders and ageing. To do so, we identify and develop  novel compounds that target GHR-related pathways and bring them to the clinic. After successful demonstration of safety and (initial) efficacy (Phase 2b), we will out-license the IP on the compound to a biopharmaceutical partner in a lucrative milestone/royalty deal. 

Our team combines young ambition with seasoned biotech entrepreneurs, innovation and funding experts, and renowned scientific leaders. The team has shown track-record in all phases of biotech development, from academic research to successful exit deals. The management of the company is performed by Maurits van den Nieuwboer PhD and Digvijay Gahtory PhD. The Scientific director is Prof. Ger Strous (Emeritus Hoogleraar Celbiologie UMC Utrecht), a key-opinion-leader in the field of the GH/IGF-1 axis.

Certifications

InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
454 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Members

Our history

Start in October 2019

  • October 2019

    Bimini Biotech founded

  • November 2019

    Bimini wins the venture challenge 2019

  • January 2020

    Bimini obtains the Take-Off Phase 1 funding

  • May 2020

    Bimini is awarded the Innowwide grant

  • October 2020

    Bimini receives pre-seed financing from UNIIQ and an angel investor

to be continued ...